Last reviewed · How we verify
Azopt 1% Ophthalmic Suspension
Azopt 1% Ophthalmic Suspension is a Carbonic anhydrase inhibitor Small molecule drug developed by Padagis LLC. It is currently in Phase 3 development for Elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Azopt is a carbonic anhydrase inhibitor that reduces aqueous humor production in the eye to lower intraocular pressure.
Azopt is a carbonic anhydrase inhibitor that reduces aqueous humor production in the eye to lower intraocular pressure. Used for Elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
At a glance
| Generic name | Azopt 1% Ophthalmic Suspension |
|---|---|
| Sponsor | Padagis LLC |
| Drug class | Carbonic anhydrase inhibitor |
| Target | Carbonic anhydrase II |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Brinzolamide, the active ingredient in Azopt, inhibits carbonic anhydrase II in the ciliary body of the eye, which decreases aqueous humor secretion. By reducing the volume of fluid produced within the eye, intraocular pressure is lowered, helping to prevent optic nerve damage and vision loss in glaucoma and ocular hypertension.
Approved indications
- Elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma
Common side effects
- Blurred vision
- Ocular discomfort or irritation
- Taste perversion (bitter taste)
- Headache
- Conjunctivitis
Key clinical trials
- Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (PHASE4)
- To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes (PHASE3)
- A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt (PHASE3)
- Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt (PHASE1, PHASE2)
- To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes (PHASE3)
- Brinzolamide-brimonidine Fixed Combination for Preventing IOP Elevation After Intravitreal Anti-VEGF Injections (NA)
- Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azopt 1% Ophthalmic Suspension CI brief — competitive landscape report
- Azopt 1% Ophthalmic Suspension updates RSS · CI watch RSS
- Padagis LLC portfolio CI
Frequently asked questions about Azopt 1% Ophthalmic Suspension
What is Azopt 1% Ophthalmic Suspension?
How does Azopt 1% Ophthalmic Suspension work?
What is Azopt 1% Ophthalmic Suspension used for?
Who makes Azopt 1% Ophthalmic Suspension?
What drug class is Azopt 1% Ophthalmic Suspension in?
What development phase is Azopt 1% Ophthalmic Suspension in?
What are the side effects of Azopt 1% Ophthalmic Suspension?
What does Azopt 1% Ophthalmic Suspension target?
Related
- Drug class: All Carbonic anhydrase inhibitor drugs
- Target: All drugs targeting Carbonic anhydrase II
- Manufacturer: Padagis LLC — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma
- Compare: Azopt 1% Ophthalmic Suspension vs similar drugs
- Pricing: Azopt 1% Ophthalmic Suspension cost, discount & access